Scholars Central

Conference abstractPublished 26 Sep 2016

GLI2, a Hedgehog signaling pathway effector, is a transcription activator of survivin expression in human tumor cells

Authors: Jiri Vachtenheim

Charles University in Prague, Czech Republic

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

GLI transcription factors are effectors of the Hedgehog/GLI signaling pathway but can act also independently of the upstream signals due to their activation by several signaling pathways deregulated in cancer cells. They have an important role in the maintenance of the tumor stemness. Survivin (a âÂ?Â?tumor proteinâÂ?) levels in tumors cells are invariably high, whereas its expression is absent or extremely low in normal tissues. The general mechanism of its high and specific expression in tumor tissue remained unclear. Here, we identified survivin as a target of GLI2 and found many putative consensus binding sites for GLI transcription factors in the survivin promoter. Inhibitors of the Hedgehog/GLI pathway, cyclopamine and GANT61, decreased the survivin promoter activity in reporter assays. GANT61, a low molecular weight GLI1/2 inhibitor, repressed endogenous survivin protein and mRNA expression levels in most cells across a large panel of tumor cell lines, while expression of genes such as SRC or BCL2 were nor changed. Chromatin immunoprecipitation showed GLI2 binding to the survivin promoter. Moreover, after transfection of ectopic GLI2 into normal human fibroblasts IMR90 which reveal no survivin or GLI2 expression, the endogenous survivin was evoked in these cells. The immunohistochemistry of human lung adenocarcinomas and other tumors revealed a correlation between the tissue regions showing strong GLI2 and survivin positivity. As the Hedgehog pathway is upregulated in all types of cancer cells, these findings substantially contribute to the explanation of uniform survivin expression in tumors.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Jiri Vachtenheim”